Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Download in electronic PDF format for $75
Abstract: Cutaneous leishmaniasis is the most common form of leishmaniasis with global incidence of about 1.5 million cases annually. The disease is endemic in Israel and caused by two types, leishmania major and leishmania tropica. The two types of cutaneous leishmaniasis in Israel are not life threatening, but the multiple skin lesions developed from the contaminated sandfly bites cause significant damage to the quality of life for a few months in patients with leishmania major and sometimes for more than a year in patients with leishmania tropica. Topical treatment for this localized skin disease is very attractive although only one medication is registered in Israel (15% paromomycin +12% methylbenzethonium chloride ointment) for the topical treatment of leishmania major. Two significant disadvantages characterize this topical medication, 1) relatively low efficacy and 2) significant irritation and pain. This article represents part 3 of a 3-part article on the topic of cutaneous leishmaniasis. Part 1 discussed the treatment option of amphotericin-B liposomal gel, part 2 discussed the treatment option of paromomycin sulfate liposomal gel, and this final part (3) discusses the treatment option of photodynamic therapy.
Related Keywords:
Eyal Zur, BScPharm, RPh, MBA, cutaneous leishmaniasis, leishmania major, leishmania tropica, Israel, topical preparations, photodynamic therapy, daylight activation, photosensitizer, 5-aminolevulinic acid hydrochloride, formulations, amphotericin B liposomal gel, paromomycin sulfate liposomal gel
Related Categories:
DERMATOLOGY, EXCIPIENTS, FORMULATIONS, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
|
Jul/Aug 2019
Pg. 288-293
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
|
May/Jun 2019
Pg. 200-207
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
PostScription: Compounding in Israel
Zur Eyal
|
May/Jun 2009
Pg. 262-263
|
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
|
Nov/Dec 2018
Pg. 446-454
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 1
Zur Eyal
|
Jan/Feb 2019
Pg. 23-31
|
Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
|
Mar/Apr 2019
Pg. 94-104
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
|
Nov/Dec 2012
Pg. 462-469
|
The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
|
Nov/Dec 2001
Pg. 462-464
|
Topical Use of Sodium Cromoglicate (Cromolyn Sodium) to Treat Atopic Dermatitis and Other Skin Allergies
Zur Eyal
|
Sep/Oct 2012
Pg. 386-393
|
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
|
Sep/Oct 2019
Pg. 376-381
|
Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
|
Jan/Feb 2014
Pg. 14-19
|
Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment
Lorentzen Jean
|
Sep/Oct 2001
Pg. 336-338
|
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Israel Alan
|
May/Jun 2003
Pg. 176-178
|
Foscarnet 2.5% Topical Cream
Allen Loyd V Jr
|
Nov/Dec 2007
Pg. 509
|
Return to Top |